Treating Duchenne means hope to
share meaningful moments

All photos here represent real VILTEPSO patients and compensated spokespeople

Duchenne muscular dystrophy (DMD) is caused by not having enough dystrophin. VILTEPSO is an exon-skipping therapy that has been granted accelerated approval based on its demonstrated increase in dystrophin in patients with DMD amenable to exon 53 skipping. Preliminary results from a Phase 3 confirmatory study of VILTEPSO have been received and are undergoing analysis and discussion with the FDA.

Healthcare provider icon

If you are aHEALTHCARE PROVIDERwho treats patients with DMD

Learn More
VILTEPSO infusion icon

If you areLOOKING FOR SUPPORT and RESOURCES

Get Information

NS Support Patient Access Solutions

The NS Support team is dedicated to assisting Duchenne patients and their caregivers throughout the VILTEPSO treatment journey. Learn about insurance coverage and financial support options for VILTEPSO.

Learn About NS Support
Prescribing Information
News Release
Stay Informed